Finally, PCSK9i efficacy in preventing CVD is also plausibly due to the pleiotropic effects on hemostasis [20]: in 21 patients with isolated hypercholesterolemia, these drugs showed a significant reduction in plasma levels of fibrinogen (p = 0.01), factor VII (p = 0.01), and plasminogen activator inhibitor-1 (PAI) (p = 0.001). This evidence concerns the gene SERPINE1 and Hypercholesterolemia.